Can intravascular ultrasound guidance modify the efficacy of drug-eluting stent over bare-metal stent in an aorto-ostial lesion?

Teruo Okabe, Akio Kawamura, Yuichiro Maekawa, Toshihisa Anzai, Shiro Iwanaga, Tsutomu Yoshikawa, Satoshi Ogawa

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: We compared the efficacy of drug-eluting stents (DESs) versus bare-metal stents (BMSs) in de novo and native aorto-ostial lesions (AOLs) guided by intravascular ultrasound (IVUS). Method: Thirty-eight patients underwent DES implantation for 38 AOLs; 35 with sirolimus-eluting stents, and three with paclitaxel-eluting stents (DES group). The control group was composed of 40 AOLs treated by BMS. The incidence of the primary composite end point of all-cause mortality, Q-wave myocardial infarction and target vessel revascularization (TVR) as TVR-major adverse cardiac event (TVR-MACE) was evaluated during a 1-year follow-up. Clinical and IVUS parameters were compared between the DES and BMS groups, and Cox hazards model was used to calculate hazard ratios of several factors for the 1-year TVR-MACE. Results: Although the vessel, plaque, and stent volumes were significantly larger after the procedures in the DES group owing to longer lesions (18.3±5.1 vs. 13.2±5.9 mm, P<001), the stent volume index (10.8±2.6 vs. 12.4±3.3, P=024) was much smaller than that in the BMS group. During the 1-year follow-up, there were 13 TVR-MACEs in all patients (13% in DES vs. 20% in BMS, P=4 by Kaplan-Meier analysis). The Cox hazards model did not indicate any specific unfavorable factor for the 1-year TVR-MACE. Conclusions: The present study showed equality between DES and BMS on de novo and native AOLs about the 1-year TVR-MACE rate, even though a DES was used in longer and bulkier lesions as compared to BMS.

Original languageEnglish
Pages (from-to)105-110
Number of pages6
JournalCardiovascular Revascularization Medicine
Volume12
Issue number2
DOIs
Publication statusPublished - 2011 Mar

Fingerprint

Drug-Eluting Stents
Stents
Metals
Proportional Hazards Models
Kaplan-Meier Estimate
Sirolimus
Paclitaxel
Myocardial Infarction
Control Groups

Keywords

  • Aorto-ostial lesion
  • Bare-metal stent
  • Drug-eluting stent
  • Intravascular ultrasound

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Can intravascular ultrasound guidance modify the efficacy of drug-eluting stent over bare-metal stent in an aorto-ostial lesion? / Okabe, Teruo; Kawamura, Akio; Maekawa, Yuichiro; Anzai, Toshihisa; Iwanaga, Shiro; Yoshikawa, Tsutomu; Ogawa, Satoshi.

In: Cardiovascular Revascularization Medicine, Vol. 12, No. 2, 03.2011, p. 105-110.

Research output: Contribution to journalArticle

Okabe, Teruo ; Kawamura, Akio ; Maekawa, Yuichiro ; Anzai, Toshihisa ; Iwanaga, Shiro ; Yoshikawa, Tsutomu ; Ogawa, Satoshi. / Can intravascular ultrasound guidance modify the efficacy of drug-eluting stent over bare-metal stent in an aorto-ostial lesion?. In: Cardiovascular Revascularization Medicine. 2011 ; Vol. 12, No. 2. pp. 105-110.
@article{6aa3f6b22d604a50bcff8a9f37fca19e,
title = "Can intravascular ultrasound guidance modify the efficacy of drug-eluting stent over bare-metal stent in an aorto-ostial lesion?",
abstract = "Purpose: We compared the efficacy of drug-eluting stents (DESs) versus bare-metal stents (BMSs) in de novo and native aorto-ostial lesions (AOLs) guided by intravascular ultrasound (IVUS). Method: Thirty-eight patients underwent DES implantation for 38 AOLs; 35 with sirolimus-eluting stents, and three with paclitaxel-eluting stents (DES group). The control group was composed of 40 AOLs treated by BMS. The incidence of the primary composite end point of all-cause mortality, Q-wave myocardial infarction and target vessel revascularization (TVR) as TVR-major adverse cardiac event (TVR-MACE) was evaluated during a 1-year follow-up. Clinical and IVUS parameters were compared between the DES and BMS groups, and Cox hazards model was used to calculate hazard ratios of several factors for the 1-year TVR-MACE. Results: Although the vessel, plaque, and stent volumes were significantly larger after the procedures in the DES group owing to longer lesions (18.3±5.1 vs. 13.2±5.9 mm, P<001), the stent volume index (10.8±2.6 vs. 12.4±3.3, P=024) was much smaller than that in the BMS group. During the 1-year follow-up, there were 13 TVR-MACEs in all patients (13{\%} in DES vs. 20{\%} in BMS, P=4 by Kaplan-Meier analysis). The Cox hazards model did not indicate any specific unfavorable factor for the 1-year TVR-MACE. Conclusions: The present study showed equality between DES and BMS on de novo and native AOLs about the 1-year TVR-MACE rate, even though a DES was used in longer and bulkier lesions as compared to BMS.",
keywords = "Aorto-ostial lesion, Bare-metal stent, Drug-eluting stent, Intravascular ultrasound",
author = "Teruo Okabe and Akio Kawamura and Yuichiro Maekawa and Toshihisa Anzai and Shiro Iwanaga and Tsutomu Yoshikawa and Satoshi Ogawa",
year = "2011",
month = "3",
doi = "10.1016/j.carrev.2010.02.002",
language = "English",
volume = "12",
pages = "105--110",
journal = "Cardiovascular Revascularization Medicine",
issn = "1553-8389",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Can intravascular ultrasound guidance modify the efficacy of drug-eluting stent over bare-metal stent in an aorto-ostial lesion?

AU - Okabe, Teruo

AU - Kawamura, Akio

AU - Maekawa, Yuichiro

AU - Anzai, Toshihisa

AU - Iwanaga, Shiro

AU - Yoshikawa, Tsutomu

AU - Ogawa, Satoshi

PY - 2011/3

Y1 - 2011/3

N2 - Purpose: We compared the efficacy of drug-eluting stents (DESs) versus bare-metal stents (BMSs) in de novo and native aorto-ostial lesions (AOLs) guided by intravascular ultrasound (IVUS). Method: Thirty-eight patients underwent DES implantation for 38 AOLs; 35 with sirolimus-eluting stents, and three with paclitaxel-eluting stents (DES group). The control group was composed of 40 AOLs treated by BMS. The incidence of the primary composite end point of all-cause mortality, Q-wave myocardial infarction and target vessel revascularization (TVR) as TVR-major adverse cardiac event (TVR-MACE) was evaluated during a 1-year follow-up. Clinical and IVUS parameters were compared between the DES and BMS groups, and Cox hazards model was used to calculate hazard ratios of several factors for the 1-year TVR-MACE. Results: Although the vessel, plaque, and stent volumes were significantly larger after the procedures in the DES group owing to longer lesions (18.3±5.1 vs. 13.2±5.9 mm, P<001), the stent volume index (10.8±2.6 vs. 12.4±3.3, P=024) was much smaller than that in the BMS group. During the 1-year follow-up, there were 13 TVR-MACEs in all patients (13% in DES vs. 20% in BMS, P=4 by Kaplan-Meier analysis). The Cox hazards model did not indicate any specific unfavorable factor for the 1-year TVR-MACE. Conclusions: The present study showed equality between DES and BMS on de novo and native AOLs about the 1-year TVR-MACE rate, even though a DES was used in longer and bulkier lesions as compared to BMS.

AB - Purpose: We compared the efficacy of drug-eluting stents (DESs) versus bare-metal stents (BMSs) in de novo and native aorto-ostial lesions (AOLs) guided by intravascular ultrasound (IVUS). Method: Thirty-eight patients underwent DES implantation for 38 AOLs; 35 with sirolimus-eluting stents, and three with paclitaxel-eluting stents (DES group). The control group was composed of 40 AOLs treated by BMS. The incidence of the primary composite end point of all-cause mortality, Q-wave myocardial infarction and target vessel revascularization (TVR) as TVR-major adverse cardiac event (TVR-MACE) was evaluated during a 1-year follow-up. Clinical and IVUS parameters were compared between the DES and BMS groups, and Cox hazards model was used to calculate hazard ratios of several factors for the 1-year TVR-MACE. Results: Although the vessel, plaque, and stent volumes were significantly larger after the procedures in the DES group owing to longer lesions (18.3±5.1 vs. 13.2±5.9 mm, P<001), the stent volume index (10.8±2.6 vs. 12.4±3.3, P=024) was much smaller than that in the BMS group. During the 1-year follow-up, there were 13 TVR-MACEs in all patients (13% in DES vs. 20% in BMS, P=4 by Kaplan-Meier analysis). The Cox hazards model did not indicate any specific unfavorable factor for the 1-year TVR-MACE. Conclusions: The present study showed equality between DES and BMS on de novo and native AOLs about the 1-year TVR-MACE rate, even though a DES was used in longer and bulkier lesions as compared to BMS.

KW - Aorto-ostial lesion

KW - Bare-metal stent

KW - Drug-eluting stent

KW - Intravascular ultrasound

UR - http://www.scopus.com/inward/record.url?scp=79952712871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952712871&partnerID=8YFLogxK

U2 - 10.1016/j.carrev.2010.02.002

DO - 10.1016/j.carrev.2010.02.002

M3 - Article

C2 - 21421189

AN - SCOPUS:79952712871

VL - 12

SP - 105

EP - 110

JO - Cardiovascular Revascularization Medicine

JF - Cardiovascular Revascularization Medicine

SN - 1553-8389

IS - 2

ER -